Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on Thursday, February 12, 2026, at 11:30 am EST.

GlobeNewsWire • Feb 5, 2026

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Fourth Quarter 2025 Financial Results

GlobeNewsWire • Jan 7, 2026

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering.

GlobeNewsWire • Jan 7, 2026

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,250,078 shares of common stock.

GlobeNewsWire • Jan 8, 2026

Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth

Following Phathom's excellent financial results for Q3, its average price target rose to $23.13, which implies an upside of about 58.8% from its current stock price. Phathom Pharmaceuticals raised its full-year 2025 revenue guidance from $165-$175 million to $170-$175 million. The main reason why vonoprazan franchise sales grew by 201% year-on-year to $49.5 million is its superior efficacy compared to PPIs.

Seeking Alpha • Nov 21, 2025

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the first patient has been dosed in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults.

GlobeNewsWire • Nov 4, 2025

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences: Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA Date: Monday, November 10, 2025Live Webcast: 3:00 pm EST Management to participate in one-on-one meetings throughout the conference Stifel 2025 Healthcare Conference in New York, NY Date: Wednesday, November 12, 2025Live Webcast: 4:40 pm EST Management to participate in one-on-one meetings throughout the conference Jefferies Global Healthcare Conference in London, UK Date: Tuesday, November 18, 2025Live Webcast: 9:30 am EST / 2:30 pm GMT Management to participate in one-on-one meetings throughout the conference 16th Annual Craig-Hallum Alpha Select Conference in New York, NY Date: Tuesday, November 18, 2025 Management to participate in one-on-one meetings throughout the conference 8th Annual Evercore Healthcare Conference in Miami, FL Date: Tuesday, December 2, 2025Live Webcast: 3:25 pm EST Management to participate in one-on-one meetings throughout the conference To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.

GlobeNewsWire • Nov 3, 2025

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. ( PHAT ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Eric Sciorilli - Director of Business Development & Investor Relations Steven Basta - CEO, President & Director Sanjeev Narula - Chief Financial & Business Officer Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Joseph Stringer - Needham & Company, LLC, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, and welcome to the Phathom Pharmaceuticals' Third Quarter 2025 Earnings Results Call.

Seeking Alpha • Oct 30, 2025

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarter Full-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026 Management to host conference call today, October 30, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J.

GlobeNewsWire • Oct 30, 2025

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $1.32 per share a year ago.

Zacks Investment Research • Oct 30, 2025